Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates-Reference-Cited by-同舟云学术

Challenges and opportunities to develop enediyne natural products as payloads for antibody-drug conjugates

Published:2021-01-01 Issue:1 Volume:4 Page:1-15
ISSN:2516-4236
Container-title:Antibody Therapeutics
language:en
Short-container-title:

Author:

Adhikari Ajeeth¹²,Shen Ben¹³⁴,Rader Christoph²^ORCID

Affiliation:

1. Department of Chemistry, The Scripps Research Institute, Jupiter, FL 33458, USA

2. Department of Immunology and Microbiology, The Scripps Research Institute, Jupiter, FL 33458, USA

3. Department of Molecular Medicine, The Scripps Research Institute, Jupiter, FL 33458, USA

4. Natural Products Discovery Center at Scripps Research, The Scripps Research Institute, Jupiter, FL 33458, USA

Abstract

Abstract Calicheamicin, the payload of the antibody-drug-conjugates (ADCs) gemtuzumab ozogamicin (Mylotarg®) and inotuzumab ozogamicin (Besponsa®), belongs to the class of enediyne natural products. Since the isolation and structural determination of the neocarzinostatin chromophore in 1985, the enediynes have attracted considerable attention for their value as DNA damaging agents in cancer chemotherapy. Due to their non-discriminatory cytotoxicity towards both cancer and healthy cells, the clinical utilization of enediyne natural products relies on conjugation to an appropriate delivery system, such as an antibody. Here, we review the current landscape of enediynes as payloads of first-generation and next-generation ADCs.

Funder

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Immunology,Immunology and Allergy

Link

http://academic.oup.com/abt/article-pdf/4/1/1/36145035/tbab001.pdf

Reference140 articles.

1. Fate of antibody-drug conjugates in cancer cells;Chalouni;J Exp Clin Cancer Res,2018

2. Pharmacokinetics of monoclonal immunoglobulin G1, F (ab')2, and Fab' in mice;Covell;Cancer Res,1986

3. Biological impediments to monoclonal antibody-based cancer immunotherapy;Christiansen;Mol Cancer Ther,2004

4. Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs);Hoffmann;Onco Targets Ther,2018

5. Current ADC linker chemistry;Jain;Pharm Res,2015

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynemicin A Derivatives as Potential Cancer Chemotherapeutics by Mutasynthesis;Helvetica Chimica Acta;2023-12

2. Cofactorless oxygenases guide anthraquinone-fused enediyne biosynthesis;Nature Chemical Biology;2023-11-09

3. Antibody–drug conjugates: Recent advances in payloads;Acta Pharmaceutica Sinica B;2023-10

4. Application of a Biocatalytic Strategy for the Preparation of Tiancimycin-Based Antibody–Drug Conjugates Revealing Key Insights into Structure–Activity Relationships;Journal of Medicinal Chemistry;2023-01-04

5. Intramolecular C–C Bond Formation Links Anthraquinone and Enediyne Scaffolds in Tiancimycin Biosynthesis;Journal of the American Chemical Society;2022-10-24